Cancer can be an immovable beast, tenacious in its numerous mechanisms to thrive and grow. However, the healthcare industry has an ever-expanding arsenal of therapies designed to thwart it, with variable levels of success. Nikki Withers speaks to Dr Jill O’Donnell-Tormey, CEO and Director of Scientific Affairs at the Cancer…
List view / Grid view
Filter the results
A star-shaped molecule along with a modified platinum drug have demonstrated success at combatting tumours with few toxic effects in mice.
Dr Mike Tocci discusses how pharmacogenomics can revolutionise medical research and improve the efficacy and quality of drugs.
The model was tested on a panel of drugs that are both still on the market or have been recalled due to adverse effects and was able to show their toxicity.
A study has revealed that the compound cannabigerol (CBG) is effective as an antibacterial in mice, by preventing bacteria from forming biofilms.
Researchers have developed a new combination of compounds called AB569 which has demonstrated success at fighting deadly pathgoens like Pseudomonas aeruginosa.
Modified sugar molecules have been developed by researchers as antiviral materials which are non-toxic to humans, according to a new study.
Researchers have developed a new body-on-chip technology that can demonstrate the pharmacokinetics and pharmacodynamics of drugs in a pre-clinical setting without the need for animal testing.
A collaboration between Elsevier and the FDA will present an algorithm for the accurate prediction of drug-induced liver injury. Drug Target Review investigates the benefits this toxicology project will bring to the drug discovery industry.
Researchers have created two new cellular models that can be used in the study of ocular diseases and drug testing.
Researchers have made a ‘Liver-Chip’ which is able to demonstrate the toxic effects of drug candidates and compounds in human patients.
Researchers have used fullerene compounds to cause NSCLC cell death in cell and animal models, which exhibited low toxicity for healthy cells.
The worldwide market for in vitro toxicology and toxicity testing is predicted to be worth $12.7 billion by the end of the forecast period.